Atomo Diagnostics Clarifies Disclosure Timing Following Lumos FDA Waiver and Capital Raise

• Material information recognized only after Lumos public waiver announcement
• Trading halt requested as precaution prior to public disclosure
• Capital raising initiated post-waiver approval with binding commitments secured
• Company denies premature disclosure or breach of continuous disclosure rules